Short answer · Medically reviewed summary · Last updated: 2026-04-06
The history of Myasthenia Gravis dates back to the 17th century, when Thomas Willis provided the first clinical description of a patient experiencing fluctuating muscle weakness that he famously termed "paralytic" symptoms. From Early Observations to Clinical Characterization While Thomas Willis documented the initial signs in 1672, it was not until the late 19th century that the condition was formally characterized. In 1891, German physician Friedrich Jolly coined the name Myasthenia Gravis, noting that the condition involved a failure of muscle contraction that could be temporarily reversed with electrical stimulation.
What is the history of Myasthenia Gravis?
History of Myasthenia Gravis: when and how it was discovered, and the milestones in research since, medically reviewed.
The history of Myasthenia Gravis dates back to the 17th century, when Thomas Willis provided the first clinical description of a patient experiencing fluctuating muscle weakness that he famously termed "paralytic" symptoms.
From Early Observations to Clinical Characterization
While Thomas Willis documented the initial signs in 1672, it was not until the late 19th century that the condition was formally characterized. In 1891, German physician Friedrich Jolly coined the name Myasthenia Gravis, noting that the condition involved a failure of muscle contraction that could be temporarily reversed with electrical stimulation. For years, patients were often misdiagnosed as having hysteria or neurasthenia, reflecting a historical lack of understanding regarding the neuromuscular junction.
Evolution of Treatment and Scientific Understanding
The 20th century marked a turning point in our comprehension of Myasthenia Gravis. In 1934, Mary Walker made a monumental discovery when she successfully treated a patient with physostigmine, observing a dramatic improvement in strength. This confirmed that the disease was linked to neurotransmission, specifically involving the chemical acetylcholine. Subsequent research revealed that Myasthenia Gravis is an autoimmune disorder, where the body’s immune system produces antibodies that attack receptors at the neuromuscular junction.
Advocacy and Modern Advancements
The formation of patient advocacy groups, such as the Myasthenia Gravis Foundation of America, shifted the narrative from isolation to community-driven research and support. Today, our understanding of Myasthenia Gravis has been revolutionized by molecular genetics and high-resolution imaging, allowing for targeted therapies like monoclonal antibodies that specifically address the underlying autoimmune pathology. These advancements have transformed a once-debilitating mystery into a highly manageable condition for many patients.
Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Myasthenia Gravis Foundation of America (MGFA)
- Orphanet: The portal for rare diseases and orphan drugs
- Online Mendelian Inheritance in Man (OMIM)
